Patents by Inventor Susan Desmond-Hellmann

Susan Desmond-Hellmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT WITH ANTI ErbB2 ANTIBODIES
    Publication number: 20190240185
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 8, 2019
    Applicant: Genentech, Inc.
    Inventors: Susan Desmond-Hellmann, Virginia Paton, Steven Shak
  • Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
    Patent number: 8206711
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 26, 2012
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
  • Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
    Publication number: 20100080769
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Application
    Filed: December 2, 2009
    Publication date: April 1, 2010
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: Antonio J. Grillo-Lopez, Christine A. White, John G. Curd, Susan Desmond-Hellmann
  • Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
    Patent number: 7682612
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: March 23, 2010
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann